ライフサイエンスコーパス: weight gain

1 uppressed olanzapine-induced hyperphagia and weight gain.

2 xpenditure, fostering overeating and further weight gain.

3 neonicotinoid contamination and Apis colony weight gain.

4 triction (CR) often fails because of rebound weight gain.

5 consumption, growth and frass production and weight gain.

6 nization in the small intestine and impaired weight gain.

7 levated energy expenditure, yielding reduced weight gain.

8 care, and they did so at the expense of male weight gain.

9 , characterized by small size and attenuated weight gain.

10 ng nutrient displacement, dental caries, and weight gain.

11 nisms underlie this process to contribute to weight gain.

12 ect genetically susceptible individuals from weight gain.

13 may nevertheless confer an increased risk of weight gain.

14 terol levels and suppression of diet-induced weight gain.

15 t hypermetabolism protected TAZ kd mice from weight gain.

16 ically, leading to metabolic dysfunction and weight gain.

17 propriate meal size, may help prevent excess weight gain.

18 ccompany symptoms of glucose intolerance and weight gain.

19 examined intervention effect on conditional weight gain.

20 ecades, has been associated with obesity and weight gain.

21 lence of inadequate or excessive gestational weight gain.

22 irth length, head circumference, or maternal weight gain.

23 with reduced microglial activation and body-weight gain.

24 sk factor for stunting at age 2 but not poor weight gain.

25 f a high-fat diet, even prior to significant weight gain.

26 reduce the potential effects of FR and SR on weight gain.

27 may increase food intake and, consequently, weight gain.

28 predisposition for antipsychotic-associated weight gain.

29 e relationship between antibiotics and human weight gain.

30 riatal networks relevant to food craving and weight gain.

31 served insulin sensitivity without affecting weight gain.

32 associated with increased caloric intake and weight gain.

33 le group included somnolence, akathisia, and weight gain.

34 g the overconsumption of food and subsequent weight gain.

35 pports the association of sulfonylureas with weight gain.

36 n, anxiety/depression, diarrhoea/nausea, and weight gain.

37 tion can result in a robust and chronic body weight gain.

38 glucose concentrations associated with body weight gain.

39 and prevent or reverse energy imbalance and weight gain [1-3].

40 , failing memory (41 [76%] vs 44 [77%]), and weight gain (46 [87%] vs 38 [68%]).

41 )] and 28 wk [increase of 21.3 g/kg maternal weight gain (95% CI: 0.6, 42.0 g)].

42 ght at 21 wk [increase of 10.5 g/kg maternal weight gain (95% CI: 1.2, 19.8 g)] and 28 wk [increase o

43 mals in group 2 had significant cessation of weight gain, abnormal biochemical test results, and vari

44 suggest that monitoring and ensuring optimal weight gain across the entire gestational spectrum begin

45 This paper investigates linear growth and weight gain among 11,946 children below the age of 5 y i

46 While weight gain among overweight/obese persons predicted inc

47 se persons predicted increased inflammation, weight gain among underweight persons predicted reduced

48 The SCN-Bmal1-KD mice also showed greater weight gain, an abnormal circadian pattern of corticoste

49 l non-surgical treatment was associated with weight gain and a quarter of patients had bariatric surg

50 w a significant positive correlation between weight gain and accumulation of perilymphatic inflammato

51 Body weight gain and adipose tissue mass were significantly r

52 glucose and insulin levels independently of weight gain and adiposity and prevented hepatic lipid ac

53 that chronic central infusion of UGN reduces weight gain and adiposity in diet-induced obese mice.

54 ncentration and alleviated diet-induced body-weight gain and adiposity in mice.

55 on, all culminating in significantly reduced weight gain and adiposity.

56 Animals in group 1 continued to have weight gain and biochemical analyses comparable to wild-

57 designed to counteract antipsychotic-induced weight gain and cardiometabolic disturbances reported li

58 ng Beijing's highly polluted air resulted in weight gain and cardiorespiratory and metabolic dysfunct

59 Surviving animals resumed normal body weight gain and clinical performance within 5 days of su

60 that the observed association between adult weight gain and colon cancer could be primarily explaine

61 biomarkers on the relationship between adult weight gain and colorectal cancer, using data from a pro

62 Attention to symptoms of weight gain and dyspnea are central tenets of patient ed

63 ta2-integrin were protected from HFD-induced weight gain and elevated adiposity.

64 rodynamic gene delivery prevents HFD-induced weight gain and fatty liver, alleviates obesity-induced

65 cies.We assessed the association of maternal weight gain and fetal growth in dichorionic twins throug

66 8 and H5N2 2014 viruses, which had decreased weight gain and fever.

67 nonuclear phagocyte population that promotes weight gain and glucose intolerance but are defined by t

68 pressing astrocytes induced exaggerated body weight gain and glucose intolerance in mice exposed to a

69 D300f (-/-) were protected from diet-induced weight gain and glucose intolerance.

70 rexpression of G3PP in rat liver lowers body weight gain and hepatic glucose production from glycerol

71 duced non-fasting and fasting blood glucose, weight gain and hepatic steatosis while protecting again

72 HFD feeding induced more weight gain and higher plasma lipids in APOE3 compared t

73 diabetic medications often result in adverse weight gain and hypoglycemic episodes.

74 mice are resistant to age- and diet-induced weight gain and insulin resistance, by mechanisms that i

75 ) by which Pemt(-/-) mice are protected from weight gain and insulin resistance.

76 h was associated with decreased diet-induced weight gain and insulin resistance.

77 secretion and reversed high-fat-diet-induced weight gain and insulin resistance.

78 The effect of dietary fish oil on weight gain and insulin sensitivity is dependent on APOE

79 possible roles of the microbiota for healthy weight gain and insulin tolerance in bears during their

80 throw light on the link between early rapid weight gain and later overweight.

81 erstanding of the relation between pregnancy weight gain and maternal and infant health complications

82 ately, these medications are associated with weight gain and metabolic complications that are especia

83 iation of sensorimotor cortex did not affect weight gain and motor performance.

84 llow-up consultations showed age-appropriate weight gain and neurodevelopment at the age of 12 months

85 the specific FA profile of diet rather than weight gain and obesity alone modulates bone metabolism

86 nce might be early events that contribute to weight gain and obesity development.

87 Weight gain and obesity have reached alarming levels.

88 typical MDD are at particularly high risk of weight gain and obesity, and Hispanics/Latinos may be es

89 Food and fluid intake, weight gain and physical activity levels were similar be

90 Despite enhanced weight gain and plasma lipid levels compared with Apoe(-

91 cle will review medications that can lead to weight gain and potential alternatives, currently approv

92 Preventing weight gain and promoting maintenance of a normal body w

93 ratio controlled inflammation, reduced body weight gain and protected from hyperglycemia on high-fat

94 ental colitis in mice, resulting in improved weight gain and survival.

95 et of rapamycin inhibition on posttransplant weight gain and the development of PTMS components postl

96 nowledges the multifactorial determinants of weight gain and the health benefits to be derived from w

97 cs such as olanzapine often induce excessive weight gain and type 2 diabetes.

98 ment of medications that are contributing to weight gain and use of approved medications for chronic

99 e several metabolic effects such as reducing weight gain and visceral fat and increasing glucose-stim

100 h-fat diet, TRIB3 MOE mice exhibited greater weight gain and worse insulin resistance in vivo compare

101 yl cytidine (AraC) blunted food intake, body weight gain, and adiposity.

102 cumference, preterm birth (<37 wk), maternal weight gain, and anemia at 24-28 wk, 30-32 wk, and 36-38

103 opmental origins of obesity, dieting-induced weight gain, and anorexia nervosa.

104 re, region, and infant plurality, sex, rapid weight gain, and baseline neurodevelopmental test result

105 Safety outcomes were death, heart failure, weight gain, and bone fracture.

106 e home has been linked to poor diet quality, weight gain, and diabetes risk, but whether having meals

107 irment) and the need to avoid hypoglycaemia, weight gain, and drug interactions further complicate th

108 ted in decreased locomotor behavior, reduced weight gain, and early postnatal lethality.

109 tein kinase C (aPKC) constrains food intake, weight gain, and glucose intolerance in both rats and mi

110 rity was associated with sedentary behavior, weight gain, and higher triglyceride and cholesterol lev

111 severe nephrotic syndrome with proteinuria, weight gain, and hyperlipidemia.

112 lic and hepatic features, is associated with weight gain, and is not as well tolerated as expected; s

113 y mass index [BMI (in kg/m(2))], gestational weight gain, and postpartum weight retention may have di

114 mendations for prepregnancy BMI, gestational weight gain, and postpartum weight retention to create m

115 ces in maternal anthropometrics, gestational weight gain, and preterm birth rate, but not in maternal

116 one, haloperidol, and olanzapine in terms of weight gain, and superior to risperidone in terms of inc

117 Weight gain appeared to increase IHTG content by generat

118 el fixed effects, maternal GWG and childhood weight gain are associated with adult body size in midli

119 -gain charts can be used to express maternal weight gain as gestational age-standardized z scores wit

120 Weight gain as measured by change in weight-for-age z sc

121 n = 25) might be associated with gestational weight gain as suggested by observational studies, altho

122 EVR with reduced-exposure TAC attenuated weight gain at 1 and 2 years posttransplant compared wit

123 Secondary outcomes included weight gain at 6, 12, and 18 months and the prevalence o

124 There was no significant difference in weight gain at 6, 12, or 18 months or in the prevalence

125 ch protected mice from high-fat diet-induced weight gain at ambient temperature (23 degrees C), but n

126 Our findings emphasise the need to prevent weight gain before pregnancy in healthy and overweight w

127 0.05 kg; 95% CI, -0.004 to 0.11 kg of added weight gain between age 2 years and 5 years).

128 ibility, greater second- and third-trimester weight gain beyond a threshold may be protective.

129 after additional adjustment for gestational weight gain, birth weight, and children's insulin concen

130 posed females had significantly greater body weight gain, body fat content, and glucose intolerance.

131 Pioglitazone-treated mice showed identical weight gain, body fat distribution, and insulin sensitiv

132 natally in WD-fed offspring had no effect on weight gain but increased metabolic flexibility while re

133 energy intake is associated with gestational weight gain, but the roles of individual macronutrients

134 repregnancy BMI (P < 0.001), higher maternal weight gain by 18 weeks' gestation (P < 0.001), and mate

135 promotes 2-AG biosynthesis, hyperphagia, and weight gain by blunting alpha-MSH production via CB1R-in

136 The presented population-based pregnancy weight-gain charts can be used to express maternal weigh

137 tely identify individuals at greater risk of weight gain, clinicians can make informed treatment deci

138 RUSF improved maternal weight gain compared with CSB+ with UNIMMAP.

139 lts are fatigue, lethargy, cold intolerance, weight gain, constipation, change in voice, and dry skin

140 gredient for diabetic people and patients in weight gain control.

141 maturation arrest/insulin resistance during weight gain could be a major factor in increasing the ca

142 enotype, gene expression, viremia level, and weight gain data to identify genetic polymorphisms that

143 6%, 3.6%); PP: -1.9% (95% CI: -5.3%, 1.4%)], weight gain [Delta = -0.7 g . kg(-1). d(-1)(95% CI: -1.3

144 ity did not significantly affect caterpillar weight gain, development, or survival.

145 Body weight gain did not differ between wild-type (WT) and mi

146 Secondary outcomes, including maternal weight gain, duration of hospital stay, readmission rate

147 erance in chow-fed rodents and causes excess weight gain during high-fat diet (HFD) feeding.

148 Gestational weight gain during pregnancy, maternal body mass index a

149 Mothers receiving RUSF had the highest weight gain during supplementation (3.4 +/- 2.6, 3.0 +/-

150 e when underweight was associated with lower weight gain during treatment.

151 tolerance, insulin resistance, and increased weight gain during, but not prior to, pregnancy.

152 Weight gain early after transplant is a risk factor for

153 er risk of diabetes but with higher risks of weight gain, edema, and fracture.

154 es showed no significant interaction between weight gain effect and age, sex, history of breastfeedin

155 obally have low birth weight, increased body weight gain, energy expenditure and hyperphagia.

156 e was associated with a greater frequency of weight gain exceeding 4.5 kg than was placebo (52.2% vs.

157 Total weight gain exceeding commonly accepted recommended guid

158 g pregnancy were associated with gestational weight gain (following Preferred Reporting Items for Sys

159 ll Asian and Samoan mothers, and gestational weight gain for Japanese mothers.

160 We created population-based pregnancy weight-gain-for-gestational-age z score charts for Swedi

161 Maternal weight gain from 0 to 13 wk (first trimester) was not as

162 The adjusted associations between maternal weight gain from 0 to 13, 14 to 20, 21 to 27, and 28 to

163 f linear regression.The mean +/- SD maternal weight gain from 0 to 13, 14 to 20, 21 to 27, and 28 to

164 Maternal weight gain from 14 to 20 and 21 to 27 wk (second trimes

165 Maternal weight gain from 14 to 20 wk was associated with increas

166 Maternal weight gain from 21 to 27 wk was associated with increas

167 EPO treatment reduced diet-induced weight gain from 9.6 +/- 1.5 to 4.2 +/- 1.4 g in male mi

168 Observed mean +/- SD weight gain from admission was 9.8 +/- 6.8 g .

169 Conditional weight gain from birth to 28 weeks was calculated.

170 We assessed weight gain from birth until 6 mo.

171 Primary outcome was weight gain (g/kg/d) from birth to the end of interventi

172 double knockout (DKO) mice are refractory to weight gain, glucose intolerance, and hepatic steatosis

173 val [CI], 1.49-8.05; P = 0.004) and maternal weight gain >/=6.0 kg by the 18th week of gestation (OR,

174 Weight gain (>/= 10 pounds) was associated with a higher

175 Greater adult weight gain (>/=300 g/year vs. <300 g/year) was associat

176 To determine whether gestational weight gain (GWG) during pregnancy and maternal body mas

177 sthma exacerbation(s) had larger gestational weight gain (GWG) in the first trimester of pregnancy (P

178 Gestational weight gain (GWG) is an important modifiable factor know

179 egnancy body mass index (BMI) or gestational weight gain (GWG) is associated with unfavorable deliver

180 (BMI; weight (kg)/height (m)2), gestational weight gain (GWG), birth size, and childhood growth fact

181 y body mass index (BMI) and (ii) gestational weight gain (GWG), with incidence of allergic and nonall

182 sociation of linear growth, independently of weight gains, has been less well studied.

183 While birth weight and weight gain have been associated with hypertension (HT),

184 ion between infant antibiotics and childhood weight gain have reported inconsistent results.

185 tment-related adverse events were reversible weight gain, hepatic transaminase elevation, and hypoalb

186 ney disease, thyroid disease, hypercalcemia, weight gain, hypertension, type 2 diabetes mellitus, car

187 in 128 g (95% CI 67, 190; p < 0.01) greater weight gain if both contained SI, but there was no diffe

188 serious adverse effects, including excessive weight gain, immune suppression, and bone loss.

189 TRF prevents excessive body weight gain, improves sleep, and attenuates age- and die

190 contributions of meal size and frequency to weight gain in a large sample of British children.

191 lance variations in BMR as a risk factor for weight gain in a typical Western population.

192 nt of genotype, and induced earlier onset of weight gain in adult female Mecp2tm1.1bird-/+ mice.

193 onged antibiotic exposure is associated with weight gain in children participating in a clinical tria

194 d in a dose-dependent manner with additional weight gain in excess of 5 kg.

195 /- 1.4 g in male mice (P < 0.001), while the weight gain in female mice was similar (4.7 +/- 2.0 g wi

196 d nesfatin-1 peptide in HFD-P and attenuated weight gain in HFD-P and MFD-P fed zebrafish, but not in

197 Weight gain in infancy was categorized into four groups

198 ) prevented the increases in food intake and weight gain in lean mice upon high-fat diet feeding, and

199 Antibiotics have been used to promote weight gain in livestock for several decades.

200 HFD resulted in 9.7% and 14.7% increased weight gain in male and female F0 respectively.

201 t metabolism with MOTS-c potently decreasing weight gain in mice on a high-fat diet.

202 increased daily caloric intake and produced weight gain in mice that had access to a high-fat diet,

203 and is required for high fat diet-dependent weight gain in mice.

204 nt with antibiotics abolished diet-dependent weight gain in Nod2 (-/-) mice, but not in wild type mic

205 EPO treatment also reduced weight gain in ovariectomized female mice, while the eff

206 food as a stratagem to decrease body fat or weight gain in overweight adolescent girls.

207 tly increased energy expenditure and reduced weight gain in recipient wild-type mice fed on a high-fa

208 6, CCHCR1 and CMPK2 affect viremia levels or weight gain in response to PRRSV infection.

209 fections, impaired glucose tolerance, and/or weight gain in the first year were more frequent with ei

210 ociations among PTSD, disordered eating, and weight gain in the Millennium Cohort Study, which includ

211 uid intake, physical activity levels or body weight gain in the rat, whereas it depleted muscle carni

212 Weight gain in the trimethoprim-sulfamethoxazole group a

213 are no accepted recommendations for maternal weight gain in twin pregnancies.We assessed the associat

214 Strategies to promote weight gain in underweight patients after AMI are worthy

215 ng effective interventions to prevent excess weight gain in young people.

216 hepatic Dpp4 was increased in mice with high weight gain, independent of liver fat content.

217 lorie diet (LCD), while downregulated during weight gain induced by high-fat diet (HFD).

218 Alcohol intake prevented body weight gain, induced the formation of uncoupling protein

219 es to evaluate the physiologic mechanisms of weight gain-induced steatosis in 27 obese people.

220 irth weight and gestational age, with weekly weight gain initiating examinations when the risk cut po

221 palatable diet for 8 weeks then separated by weight gain into DIO-prone and DIO-resistant subgroups.

222 Weight gain is a common and serious adverse effect of an

223 Rapid infant weight gain is associated with later obesity, but interv

224 Early rapid weight gain is associated with later overweight, which i

225 Weight gain is attributed to increased fat deposits pote

226 However, despite weight gain, KCl prevented worsening of fasting glucose.

227 ular resistance, oxygenation capacity), lung weight gain, levels of proteins, lactate dehydrogenase,

228 To examine incremental weight gain, linear growth, and clinical features in the

229 ic syndrome as evident from a markedly lower weight gain, lower total body and liver fat accumulation

230 ible) to avoid agents that can contribute to weight gain, many patients are still unable to achieve c

231 for maternal sociodemographics, gestational weight gain, maternal and paternal height, and (for post

232 ng prepregnancy body mass index, gestational weight gain, maternal smoking during pregnancy, and brea

233 Interventions targeting childhood weight gain may provide one path to mitigating genetic r

234 regression was used to express the repeated weight-gain measurements as a function of gestational ag

235 gnancy is associated with higher gestational weight gain (n = 52).

236 anging the risk factor profile to the lowest weight gain, no alcohol consumption, high physical activ

237 cytokines that was secondary to reduction in weight gain not present in the other groups.

238 5.17 kg (4.71-5.66), respectively, versus a weight gain of 1.15 kg (0.70-1.61) with insulin glargine

239 s gained weight, with an overall mean +/- SD weight gain of 1.24 +/- 2.03 kg.

240 ere we show that the gut microbiota promotes weight gain of both whole body and the gut in individual

241 s group-housed female mice display increased weight gain on high-fat diet, reduced behavioral despair

242 However, rates of greater than 15% weight gain on valproate, olanzapine, and quetiapine wer

243 ibranor was well tolerated and did not cause weight gain or cardiac events, but did produce a mild, r

244 s predefined by improved per-patient rate of weight gain or carotid artery echodensity; 71.0% of part

245 ancy did not significantly increase maternal weight gain or improve birth size but did reduce materna

246 ciation between antibiotic use and excessive weight gain or obesity in healthy infants and young chil

247 a stronger influence than either gestational weight gain or postpartum weight retention.

248 o this antibiotic has a concurrent effect on weight gain or the prevalence of overweight or obesity i

249 no impact of insecticide exposure on colony weight gain, or the number or mass of sexuals produced,

250 k in FTO carriers and lead to an exaggerated weight gain over time.

251 score at discharge (P < 0.008), and greater weight gain (P < 0.05).

252 Since weight gain perpetuates metabolic alterations, this inte

253 nimals with dietary n-3 PUFAs decreased body-weight gain, plasma lipids, and insulin (P < 0.05) and i

254 ipose cell size and greater enlargement with weight gain predicted decline in IMGU, as did increase i

255 inopathy of Prematurity (CHOP-ROP) postnatal weight gain predictive model are 2 approaches for improv

256 Observed weight-gain ranges were contrasted with current Institut

257 ght (BW), gestational age at birth (GA), and weight gain rate to predict the risk of severe retinopat

258 urrent Institute of Medicine (IOM) pregnancy weight-gain recommendations.

259 as found to be effective in suppressing body weight gain relative to control in a diet-induced obese

260 PR158 may influence EE; however, its role in weight gain remains controversial, as it either had no a

261 The association between PTSD and weight gain resulting from compensatory behaviors (vomit

262 to improve metabolic flexibility and reduce weight gain risk.

263 In addition to lifestyle changes, weight gain secondary to medications is an important mod

264 use of drugs to treat parkinsonian symptoms, weight gain, sedation, increase in prolactin release, ov

265 Excessive weight gain should be avoided, as incident diabetes was

266 hout overt clinical disease, but showed body weight gains significantly reduced by 6.5-11.4% beginnin

267 d2 (-/-) HFD mice transferred sensitivity to weight gain, steatosis, and hyperglycemia to wild type g

268 doubles the risk of psoriasis, and long-term weight gain substantially increases psoriasis risk.

269 renal and endocrine adverse events but less weight gain than commonly used alternative mood stabiliz

270 High-fat diet (HFD)-fed MNK2-KO show less weight gain than wild-type animals, and improved glucose

271 avonoid intake has been associated with less weight gain, there are limited data on its impact on fat

272 ed to other variables that are predictive of weight gain to inform the design of obesity-preventive p

273 symptoms and resulted in the restoration of weight gain to the level of uninfected pigs.

274 Weight-gain velocity was slightly higher in the shortest

275 After 6 weeks, weight gain was associated with an increase in mean (SD)

276 More than 5 kg first-trimester weight gain was associated with an increased risk of ast

277 femur and humerus lengths at 28 wk.Maternal weight gain was associated with dichorionic twin fetal g

278 Greater infant weight gain was associated with higher FEV1 but lower FE

279 Weight gain was more rapid with quetiapine-ER (p=0.0008)

280 Weight gain was predicted by low mean (SD) baseline rewa

281 Weight gain was similar between UPI/OIR and control/OIR

282 Weight gain was similar in the lower- and higher-protein

283 reated patients were akathisia and insomnia; weight gain was slightly higher with cariprazine than wi

284 ariability have been shown to predict future weight gain.We examined whether the brain-reward respons

285 size for gestational age, and greater infant weight gain were across the full ranges associated with

286 birth, low birth weight, and greater infant weight gain were associated with an increased risk of ch

287 nal obesity and higher early-mid gestational weight gain were associated with NAFLD in female offspri

288 thermore, olanzapine-induced hyperphagia and weight gain were blunted in mice lacking the serotonin 2

289 Rates of weight gain were not greater in the bottom BMR group (0.

290 ment, diet consumption, frass production and weight gain were observed at sub-lethal dose rates.

291 While hyperleptinemia and pre-pregnancy weight gain were present in all db/+mice across the four

292 ut not parental age nor maternal gestational weight gain, were associated with NAFLD in male offsprin

293 Many antipsychotics promote weight gain, which can lead to non-compliance and relaps

294 n of Cadm1 in excitatory neurons facilitated weight gain while exacerbating energy expenditure.

295 t-dependent microglia expansion hinders body weight gain while preventing central and peripheral infl

296 al age, size for gestational age, and infant weight gain with childhood lung function and asthma (age

297 so associated with weight loss compared with weight gain with glargine (-1.4 kg for degludec/liraglut

298 istration of 11 reduced food intake and body weight gain without causing CNS-related malaise.

299 cy was categorized into four groups based on weight gain z-scores: slow (<-0.67), on track (-0.67 to

300 Minimal intermittent stimulation led to body weight gain; ZI GABA neuron ablation reduced weight.